Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACHIEV: Broadly Neutralizing Antibodies and Therapeutic Vaccination for HIV Remission
NCT06484335Phase 1Recruiting
- Sponsor
- Henry M. Jackson Foundation for the Advancement of Military Medicine
- Start
- Mar 2025
- Primary completion
- Jul 2029
- Modality
- Prophylactic Vaccines, Viral Vectors, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VRC07-523LS, PGDM1400LS, ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv4 and 1 more in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Henry M. Jackson Foundation for the Advancement of Military Medicine. Primary endpoints: Safety of VRC07-523LS and PGDM1400LS in combination with therapeutic vaccination at 100 weeks and Viral load setpoint after viral rebound during ATI at 50 weeks. Started Mar 2025; status: recruiting.
02
Drugs
VRC07-523LSPGDM1400LSChAdOx1.tHIVconsv1ChAdOx1.HIVconsv62MVA.tHIVconsv4
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06484335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06484335.